A Phase1b Clinical Study of the Oral PI3Kd Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

被引：1

作者：

Qiu, Lugui ^{[1
,2
]}

Li, Zhiming ^{[3
]}

Huang, Yunhong ^{[4
]}

Liu, Ligen ^{[5
]}

Liu, Lihong ^{[6
]}

Guo, Ye ^{[7
]}

Deng, Lan ^{[8
]}

Yang, Haiyan ^{[9
]}

CA, Zhen, I ^{[10
,12
]}

Ye, Xu ^{[11
]}

Wang, Zhen

Bao, Hanying ^{[13
]}

Xu, Zusheng ^{[13
]}

Zheng, Binghua ^{[13
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China

[3] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China

[4] Guizhou Med Univ, Dept Lymphoma, Affiliated Canc Hosp, Guiyang, Peoples R China

[5] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China

[6] Hebei Med Univ, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[7] Tongji Univ, Shanghai Dongfang Hosp, Dept Med Oncol, Shanghai, Peoples R China

[8] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Hematol, Sch Med, Shanghai, Peoples R China

[9] Univ Chinese Acad Sci, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China

[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China

[12] Linyi Canc Hosp, Linyi, Peoples R China

[13] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148276

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3576

引用

页数：5

共 50 条

[1] FCN-289, a novel, potent and selective PI3Kd inhibitor for the treatment of B-cell malignancies
Lin, Shu
Zhou, Zuwen
Tan, Rui
Xu, Hua
Zhang, Huajie
Zhang, Weipeng
Chen, Ling
Yang, Lijun
Zhao, Xingdong
Liu, Yanxin
Zou, Zongyao
Gao, Yuwei
Zhou, Jiashu
Wang, Weibo
CANCER RESEARCH, 2022, 82 (12)
[2] Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kd Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma
Wang, Tingyu
Sun, Xiuhua
Qiu, Lihua
Su, Hang
Cao, Junning
Li, Zhiming
Song, Yuqin
Zhang, Li
Li, Dengju
Wu, Huijing
Zhang, Wei
Li, Junmin
Zhou, Keshu
Zhou, Hui
Yang, Yu
Li, Zhifeng
Cen, Hong
Cai, Zhen
Zhang, Zhihui
Fu, Weijun
Jie, Jin
Li, Fei
Wu, Weixin
Gu, Xuekui
Zhu, Weiliang
Liu, Lihong
Li, Zengjun
Yi, Shuhua
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
BLOOD, 2023, 142
[3] The Oral PI3Kd Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Wang, Tingyu
Sun, Xiuhua
Qiu, Lihua
Su, Hang
Cao, Junning
Li, Zhiming
Song, Yuqin
Zhang, Li
Li, Dengju
Wu, Huijing
Zhang, Wei
Li, Junmin
Zhou, Keshu
Zhou, Hui
Yang, Yu
Li, Zhifeng
Cen, Hong
Cai, Zhen
Zhang, Zhihui
Fu, Weijun
Jin, Jie
Li, Fei
Wu, Weixin
Gu, Xuekui
Zhu, Weiliang
Liu, Lihong
Li, Zengjun
Yi, Shuhua
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1440 - 1449
[4] A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies
Liu, Wei
Huang, Yunhong
Yang, Haiyan
Li, Zhiming
Cai, Zhen
Wang, Zhen
Liu, Lihong
Guo, Ye
Liu, Ligen
Huang, Rui
Ye, Xu
Qiu, Lugui
BLOOD, 2023, 142
[5] Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
Li, Jin
Xue, Junli
Liu, Tianshu
Feng, Yi
Xu, Nong
Huang, Jianjin
Yin, Yongmei
Zhang, Jun
Mou, Haibo
Shentu, Jiangzhong
Bao, Hanying
Xu, Zusheng
Xu, Zuhong
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 241 - 251
[6] Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
Zinzani, Pier Luigi
Trneny, Marek
Ribrag, Vincent
Zilioli, Vittorio Ruggero
Walewski, Jan
Christensen, Jacob Haaber
Delwail, Vincent
Rodriguez, Guillermo
Venugopal, Parameswaran
Coleman, Morton
Dartigeas, Caroline
Patti, Caterina
Pane, Fabrizio
Jurczak, Wojciech
Taszner, Michal
Paneesha, Shankara
Zheng, Fred
Demarini, Douglas J.
Jiang, Wei
Gilmartin, Aidan
Mehta, Amitkumar
ECLINICALMEDICINE, 2023, 62
[7] Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
Bo Jiang
Junyuan Qi
Yuqin Song
Zengjun Li
Meifeng Tu
Lingyan Ping
Zongliang Liu
Hanying Bao
Zusheng Xu
Lugui Qiu
Journal of Hematology & Oncology, 14
[8] Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
Jiang, Bo
Qi, Junyuan
Song, Yuqin
Li, Zengjun
Tu, Meifeng
Ping, Lingyan
Liu, Zongliang
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[9] Amdizalisib (HMPL-689), a highly selective PI3Kd inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models
Hu, Jia
Wang, Jianhan
Dai, Xiaoming
He, Jianlin
Liang, Junqing
Yu, Ying
Yu, Juntao
Yang, Na
Wang, Linfang
Cai, Yu
Li, Xiong
Qing, Weiguo
Ren, Yongxin
Su, Weiguo
CANCER RESEARCH, 2022, 82 (12)
[10] Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
Liu, Xiaochuan
Wang, Aoli
Liang, Xiaofei
Chen, Cheng
Liu, Juanjuan
Zhao, Zheng
Wu, Hong
Deng, Yuanxin
Wang, Li
Wang, Beilei
Wu, Jiaxin
Liu, Feiyang
Fernandes, Stacey M.
Adamia, Sophia
Stone, Richard M.
Galinsky, Ilene A.
Brown, Jennifer R.
Griffin, James D.
Zhang, Shanchun
Loh, Teckpeng
Zhang, Xin
Wang, Wenchao
Weisberg, Ellen L.
Liu, Jing
Liu, Qingsong
ONCOTARGET, 2016, 7 (22) : 32641 - 32651

← 1 2 3 4 5 →